Retatrutide

Retatrutide is an investigational triple agonist peptide targeting GLP-1, GIP, and glucagon receptors, studied for weight loss, appetite regulation, metabolic health, and body-composition optimization.

Profile · 01

Overview

Retatrutide is an investigational triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. It is being studied for weight loss, appetite regulation, metabolic health, and body-composition optimization.

Unlike single-pathway GLP-1 agonists, Retatrutide combines appetite suppression with increased energy expenditure, making it one of the most aggressive metabolic-regulation signals currently under investigation.

At a Glance

Goal
Fat loss, metabolic optimization, and appetite regulation via simultaneous GLP-1, GIP, and glucagon receptor activation
Categories
Fat LossMetabolic HealthAppetite ControlBody Composition
Synergistic
Protein intake · Electrolytes · Resistance training
Profile · 02

Protocol

Structured weekly titration approach based on clinical trial patterns, escalating every four weeks toward the target therapeutic range.

Typical weekly range
1–12 mg once weekly (titrated)
Start
1 mg weekly for the first 4 weeks to assess tolerability
Titration
Increase the weekly dose every 4 weeks as tolerated
Target
6–12 mg weekly during the maintenance phase
Frequency
Once weekly (subcutaneous)
Cycle Length
12–24 weeks per cycle
Route
Subcutaneous
Cycle
12–24 weeks per cycle

Inject once weekly subcutaneously, beginning at 1 mg and increasing every 4 weeks based on tolerability. Aggressive titration is associated with greater GI side effects (nausea, vomiting, diarrhea); slower titration is generally better tolerated. Hydration, adequate protein intake, and resistance training are critical adjuncts due to the rapid fat-loss signaling and the risk of lean mass loss.

Dose progression

Weeks 1–4
1 mg
Weeks 5–8
2–4 mg
Weeks 9+
6–12 mg

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Profile · 03

Videos

Science · 01

How Retatrutide works.

Retatrutide activates three metabolic pathways simultaneously. GLP-1 receptor activation drives appetite suppression, satiety signaling, and delayed gastric emptying. GIP receptor activation modulates insulin response and supports nutrient partitioning. Glucagon receptor activation increases energy expenditure and promotes fat oxidation. The triple-agonist activity produces a combined effect of reduced caloric intake and increased metabolic output, distinguishing it from single-pathway GLP-1 agonists. Clinical trial data has demonstrated significant weight reduction, improved glycemic control, and reductions in liver fat in NAFLD/MAFLD models.

Science · 02

Effects

Observations from clinical or preclinical literature.

Significant fat loss observed in clinical trials, including substantial reductions in body weight at higher dose tiers
Appetite suppression and improved satiety, supporting adherence to a hypocaloric intake
Enhanced metabolic efficiency through increased energy expenditure (glucagon-receptor effect)
Improved glucose regulation and insulin response (GLP-1 / GIP effects)
Reduction in visceral and liver fat in clinical and preclinical models
Common GI side effects: nausea, vomiting, diarrhea or constipation — typically dose- and titration-dependent
Fatigue and dehydration risk, particularly during rapid weight loss phases
Rapid weight loss can predispose to lean mass loss without adequate protein intake and resistance training
Science · 03

Caution

Not for use during pregnancy or breastfeeding
Avoid in pediatric populations
Use caution in individuals with severe gastrointestinal conditions or a history of gastroparesis
Monitor hydration, food intake, and metabolic markers closely throughout the protocol
Medical supervision is required for any clinical use; investigational status means long-term safety data is still emerging

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Protein intake
Critical for lean-mass preservation during aggressive fat-loss signaling; aim for adequate daily protein with each meal.
Electrolytes
Sodium, potassium, and magnesium support hydration and reduce fatigue/cramping during rapid weight loss.
Omega-3 fatty acids
Support metabolic and lipid-profile improvements complementary to triple-agonist activity.
Micronutrient sufficiency
Reduced caloric intake increases the risk of micronutrient gaps; a comprehensive multivitamin or food-first plan is recommended.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Maintain adequate protein intake during weight loss to preserve lean mass
Incorporate resistance training to defend muscle mass against the catabolic pressure of rapid fat loss
Prioritize hydration and electrolyte balance — appetite suppression often reduces fluid intake along with food
Ensure sufficient sleep and recovery; under-recovery compounds GI and fatigue side effects
Avoid sustained under-eating: extreme caloric deficits combined with appetite suppression accelerate lean-mass loss
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Body weight — weekly trend tracking is more informative than daily readings
  2. Body fat percentage and lean mass — track via DEXA, BIA, or consistent caliper measurements
  3. Resting heart rate and HRV — early signals of recovery debt or excessive stress on the system
  4. Recovery score and sleep quality — adherence to titration and recovery is essential at higher doses
  5. Appetite levels and energy levels — useful for calibrating dose escalation and adherence
  6. GI tolerance — track nausea, bowel patterns, and hydration status to inform titration pacing
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

Fasting glucose
Track glycemic impact of GIP/GLP-1 receptor activation.
HbA1c
Longer-term glycemic marker; useful for evaluating metabolic improvement over the cycle.
Fasting insulin
Helps assess insulin sensitivity changes alongside fasting glucose.
Lipid panel
Monitor triglycerides, LDL, and HDL changes through the protocol.
Liver enzymes
Baseline and periodic monitoring; relevant for liver-fat changes.
Kidney function
Hydration changes and rapid weight loss can affect renal markers.
Electrolytes
Important given hydration and intake changes; sodium, potassium, magnesium worth tracking.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 10 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean vial stopper and skin with alcohol swabs; allow to air-dry completely
Pinch a skinfold at the injection site (abdomen, thigh, or upper arm)
Insert needle at 90° (if adequate subcutaneous fat) or 45° (if lean)
Release the pinch, then inject slowly; wait 2–3 seconds before withdrawing
Rotate injection sites systematically across abdomen, thighs, and upper arms to prevent lipohypertrophy
Dispose of used syringes immediately in a puncture-proof sharps container

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Titrate slowly to improve tolerability; aggressive escalation increases the rate of GI side effects
Hydration is critical — appetite suppression can reduce fluid intake along with food intake
Do not construct vial-based dosing math without a verified post-reconstitution concentration
Rapid fat loss requires active lean-mass preservation — protein intake and resistance training are not optional
Monitor nutritional intake closely; reduced appetite combined with rapid loss raises the risk of micronutrient deficiencies
Retatrutide is investigational and not FDA-approved; any use should comply with applicable laws and involve qualified medical supervision
Reference · 02

References

  1. ClinicalTrials.gov
    Public registry for Retatrutide clinical trials and outcomes data.
    https://clinicaltrials.gov/
  2. CDC
    "Vaccine administration: subcutaneous route (angle/site; no aspiration)".
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
  3. PMC
    "Pharmacologic considerations of the subcutaneous route".
    https://pmc.ncbi.nlm.nih.gov/articles/PMC6822791/
On this page